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TO THE EDITOR
The molecular events underlying the
oncogenesis of cutaneous T-cell lym-
phomas (CTCLs) remain largely
unknown, especially when considering
primary or driver mutations. Global
genomic approaches have revealed the
existence of recurrent chromosomal
or genetic alterations, some of which
having potential diagnosis or prognosis
value (Scarisbrick et al., 2000; Vermeer
et al., 2008; van Doorn et al., 2009;
Laharanne et al., 2010a, 2010b;
Cristofoletti et al., 2013). However,
no speciﬁc gene mutation is currently
assessed for the management of patients
with CTCLs.
Vaque et al. (2014) recently identiﬁed
somatic mutations of the Phospholipase
C Gamma 1 (PLCG1) gene in about
20% of epidermotropic CTCLs, being
notably more frequent in transformed/
tumoral mycosis fungoides (T-MF; 8/30
cases) and the Sézary syndrome (SS; 1/2
cases) than in erythrodermic and
folliculotropic mycosis fungoides (1/20
cases). They reported a c.1034C4T/p.
S345F mutation in exon 11 in nine
patients (eight T-MF and one SS) and a
c.1559C4T/p.S520F mutation in exon
15 (in one erythrodermic mycosis fungo-
ides case). Such mutations, especially the
p.S345F mutation, conferred enhanced
signaling capacity and transforming
property. Finally, PLCG1 mutations were
suggested to be possibly associated with a
higher rate of disease-related death
(Vaque et al., 2014).
These ﬁndings prompted us to inves-
tigate the PLCG1 gene status in our
series of CTCLs, including T-MF (n= 37)
and SS (n= 39). We also studied other
CTCL subtypes including lymphomatoid
papulosis (LyP; n= 4), cutaneous ana-
plastic large cell lymphomas (c-ALCL,
n= 14), and the following T cell or
CTCL cell lines: MyLa, SeAX, HH,
Hut78, FEPD, and 1301 (for origin see
Chevret et al. (2014)).
All cases were retrieved from the
Aquitaine database of cutaneous
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lymphomas, with approval from the
regional bioethics committee and
informed written consent, in accor-
dance with the Declaration of Helsinki
Principles. Skin or blood* samples (*for
patients with SS) were analyzed. The
selected cases contained at least 40% of
tumor cells, as found by histo/
cytopathological or ﬂow cytometric
evaluation. DNA was extracted from
frozen CTCL samples or cell lines with
the DNA easy kit (Qiagen, Courtaboeuf,
France). All exhibited a dominant
monoclonal rearrangement of the
T-cell receptor gamma (TCRG) gene
(Beylot-Barry et al., 2001), as well as
chromosomal imbalances (Laharanne
et al., 2010b). In cases with PLCG1
mutation, constitutional DNA was
extracted from histologically normal
tissue and checked for the absence of
the monoclonal TCRG gene rearrange-
ment. The mutational status of PLCG1
exon 11 and 15 was determined by
high-resolution melting (HRM) analysis
on a LC480 device (Roche Diagnostics,
Meylan, France), followed by Sanger
sequencing for samples exhibiting
variant proﬁles, as reported for BRAF
status determination (Boursault et al.,
2013). The primers used were the
following: 5′-GCCCATCTGACCATACC
TAC-3′ and 5′-TGGACCCCACGCACAC
TCA-3′ (exon 11) and 5′-CTCACAAGTC
CCTCTTTGGTC-3′ and 5′-GACCTGA
GCTGGTTCCTCAC-3′ (exon 15).
Only one of the 37 tested T-MF cases
(2.7%) from our series harbored a muta-
tion in exon 11 (c.1025A4G/p.D342G;
case 48, Figure 1, Table 1). Two out of
the 39 tested SS cases (5%) exhi-
bited exon 11 mutations, the c.1024
G4A/p.D342N mutation (case 75) and
the c.1034C4T/p.S345F mutation (case
58; Figure 1,Table 1), the latter being
previously reported to be a recurrent
event in CTCLs (Vaque et al., 2014). All
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Figure 1. Identiﬁcation of Phospholipase C Gamma 1 (PLCG1) exon 11 mutations in cutaneous T-cell lymphoma (CTCL) samples. (a) High-resolution melting
(HRM) curves and (b) Sanger sequencing proﬁles (partial sequence, sense strand) of PLCG1 exon 11 PCR products obtained from normal and CTCL DNA samples.
The three CTCL cases (one transformed/tumoral mycosis fungoides (T-MF) and two Sézary syndrome (SS)) in which PLCG1 exon 11 mutations were identiﬁed are
illustrated.
Table 1. CTCL patient features and PLCG1 status
Diagnosis
Number
of cases Gender
Mean
age± SD
(years) Status PLCG1 exon 11
Status
PLCG1
exon 15
cALCL N=14 F= 3
M= 7
58±6 All WT All WT
LyP N=4 F= 3
M= 1
30±15 All WT All WT
MF N=37
(MF= 5;
T-MF=32)
F= 14
M= 23
68±9 1 Mutant (c.1025A4G;
p.D342G) 40 WT
All WT
SS N=39 F= 17
M= 22
70±6 1 Mutant (c.1034 C4T;
p.S345F)
1 mutant (c.1024 G4A;
p.D342N)
46 WT
All WT
Abbreviations: cALCL, cutaneous anaplastic large cell lymphomas; F, female; LyP, lymphomatoid
papulosis; M, male; MF, mycosis fungoide; SS, Sézary syndrome; T-MF, transformed mycosis
fungoides; WT, wild type.
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three mutations were somatic, as not
detected in the control constitutional
DNA. Interestingly, the p.D342G and
p.D342N mutations had not been
reported either in CTCLs (Vaque et al.,
2014) or in other types of cancers (http://
cancer.sanger.ac.uk/cosmic/gene/analysis?
ln=PLCG1#dist). According to the
PROVEAN (http://provean.jcvi.org/seq_
submit.php) or PolyPhen (http://genetics.
bwh.harvard.edu/pph2/) software analysis,
they were predicted to alter the function of
the PLCG1 protein catalytic domain. In the
two mutated SS cases, the same mutation
was detected in blood samples at two
time points of the disease, with a 5-year
(case 58) and a 1-year (case 75) interval,
respectively (Figure 1, Table 1). Although
all cases contained at least 40% of tumor
cells, the mutated allele was more promi-
nent in samples from the T-MF case 48
and the SS case 75 than in the SS case 58
(Figure 1), suggesting a possible tumor
cell heterogeneity for the PCLG1 status in
this case. In addition, none of our T-MF
and SS cases exhibited PLCG1 exon 15
mutation, and none of the tested c-ALCL
and LyP cases and T-cell leukemia/CTCL
cell lines showed mutations of PLCG1
exons 11 or 15.
We thus report a low frequency of
PLCG1 mutations in our T-MF (1 of 37,
2.7%) and SS (2 of 39, 5%) cases and
the fact that the c.1034C4T/p.S345F
mutation is quite uncommon in CTCLs
(one out of the three mutations found in
the 94 CTCL patients tested). We also
document the absence of PLCG1 exon
11 and 15 mutations in the tested
c-ALCL and LyP cases, as well as in
the main CTCL cell lines.
For SS, differences in sample numbers
can explain the discrepancy between
frequencies of PLCG1 mutations found
in our study (2/39 cases) and the ﬁrst
one (1/2 cases; Vaque et al., 2014). For
T-MF, we and the previous report
analyzed comparable number of sam-
ples; thus, the distinct mutation frequen-
cies (1/37 vs. 8/30) may come from
technical aspects. Indeed, in the pre-
vious study, ﬁve out of the nine cases
harboring the c.1034C4T/p.S345F were
identiﬁed only with a sensitive allele-
speciﬁc quantitative PCR assay (Vaque
et al., 2014). On the other hand, our
HRM/Sanger sequencing strategy identi-
ﬁed two previously unknown PLCG1
mutations affecting the catalytic domain
that would have been missed by the
allele-speciﬁc mutation analysis used
by our colleagues (Vaque et al., 2014;
Manso et al., 2015).
To exclude technical bias, we
checked the sensitivity of our metho-
dology by diluting the mutated samples
within normal DNA. As illustrated for
sample 2 from case 75, containing 40%
of Sézary cells (Figure 1 and Supple-
mentary Figure S1 online -Pure-),
dilution up to 4-fold still allowed a
clear detection of variant HRM proﬁle,
as well as a mutant peak on Sanger
sequencing proﬁles (Supplementary
Figure S1A and S1B online). Higher
dilutions (8-fold) yielded normal HRM
proﬁles, and the mutation was barely
detected by Sanger sequencing. There-
fore, our approach is capable to detect
PLCG1 mutation in samples with 10%
of tumor cells (5% of mutant allele) in
accordance with our previous evalua-
tion of this technique for BRAF analysis
in melanomas (Boursault et al., 2013).
Using allele-speciﬁc mutation analysis,
the same group reported the presence of
the PLCG1S345F in about 13% of periph-
eral T-cell lymphoma, with signiﬁcant
association with CD30 expression and
p50 nuclear expression, suggesting an
increased NF-kB activity (Manso et al.,
2015). Such an association was not
observed in our CTCL series, which also
includes CD30+ T-MF cases and CD30+
cutaneous lymphoproliferative disorders
with abundant tumor cell content
(Fauconneau et al., 2015).
If assessment of the PLCG1 muta-
tions, notably the p.S345F mutation, is
only feasible with highly sensitive
methods, especially in our samples
containing more than 40% of tumor
cells, this would suggest that PLCG1
mutations do not represent an initiating
oncogenic event but may be acquired
by some aggressive subclones with
possible prognosis impact on the overall
survival in CTCL and PTCL (Vaque
et al., 2014; Manso et al., 2015).
Further investigations by other groups
and next-generation sequencing
techniques are required to establish
the real prevalence of PLCG1 muta-
tions, which appeared unusual in
our series of otherwise well-charac-
terized CTCL subtypes (Laharanne
et al., 2010b; Chevret et al., 2014;
Fauconneau et al., 2015).
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